Javle, M., Borbath, I., Clarke, S., Hitre, E., Louvet, C., Macarulla, T., . . . Abou-Alfa, G. (2019). Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial. Annals of oncology, 30, . https://doi.org/10.1093/annonc/mdz155.224
Chicago-Zitierstil (17. Ausg.)Javle, Milind, et al. "Phase 3 Multicenter, Open-label, Randomized Study of Infigratinib Versus Gemcitabine Plus Cisplatin in the First-line Treatment of Patients with Advanced Cholangiocarcinoma with FGFR2 Gene Fusions/translocations: The PROOF Trial." Annals of Oncology 30 (2019). https://doi.org/10.1093/annonc/mdz155.224.
MLA-Zitierstil (9. Ausg.)Javle, Milind, et al. "Phase 3 Multicenter, Open-label, Randomized Study of Infigratinib Versus Gemcitabine Plus Cisplatin in the First-line Treatment of Patients with Advanced Cholangiocarcinoma with FGFR2 Gene Fusions/translocations: The PROOF Trial." Annals of Oncology, vol. 30, 2019, https://doi.org/10.1093/annonc/mdz155.224.